Gossamer Bio (GOSS) Receives a Buy From Piper Sandler

TipRanksJul 15 06:48 ET

Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says

Oppenheimer initiated coverage on Gossamer Bio Inc (NASDAQ:GOSS), a clinical-stage biopharmaceutical company, with an Outperform rating and a price target of $9. Gossamer Bio is focused on developing

BenzingaJun 25 14:39 ET

Gossamer Bio And 2 Other Stocks Under $2 Insiders Are Buying

The Dow Jones index closed higher by over 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders in

BenzingaJun 25 08:51 ET

Express News | Gossamer Bio Inc : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $9

ReutersJun 25 08:20 ET

Express News | Gossamer Bio Shares Are Trading Higher After Oppenheimer Initiated Coverage With an Outperform Rating and a Price Target of $9

BenzingaJun 25 07:46 ET

Gossamer Bio Initiated at Outperform by Oppenheimer

Gossamer Bio Initiated at Outperform by Oppenheimer

Dow JonesJun 25 05:51 ET